(Q29620913)

8 January 2018

title

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer (English)

1 reference

8 January 2018

non-small-cell lung carcinoma

main subject

nivolumab

0 references

docetaxel

0 references

0 references

author

Charles Rudin

20

1 reference

8 January 2018

David E. Gerber

David E Gerber

18

0 references

Enriqueta Felip

Enriqueta Felip

9

0 references

Everett E Vokes

8

Everett E Vokes

1 reference

8 January 2018

PMCID

5705936

George R Blumenschein

23

George R Blumenschein

1 reference

8 January 2018

Hossein Borghaei

1

Hossein Borghaei

1 reference

8 January 2018

David R Spigel

4

David R Spigel

1 reference

8 January 2018

Neal E Ready

6

Neal E Ready

1 reference

8 January 2018

Esther Holgado

10

Esther Holgado

1 reference

8 January 2018

Fabrice Barlesi

11

Fabrice Barlesi

1 reference

8 January 2018

Jérôme Fayette

15

Jérôme Fayette

1 reference

8 January 2018

Naiyer A Rizvi

21

Naiyer Rizvi

1 reference

8 January 2018

Lucio Crino

22

Lucio Crinò

1 reference

8 January 2018

Scott J Antonia

24

Scott J Antonia

1 reference

8 January 2018

Julie R Brahmer

28

Julie R Brahmer

1 reference

8 January 2018

author name string

Luis Paz-Ares

2

1 reference

8 January 2018

Leora Horn

3

1 reference

8 January 2018

Martin Steins

5

1 reference

8 January 2018

Laura Q Chow

7

1 reference

8 January 2018

Martin Kohlhäufl

12

1 reference

8 January 2018

Oscar Arrieta

13

1 reference

8 January 2018

Marco Angelo Burgio

14

1 reference

8 January 2018

Hervé Lena

16

1 reference

8 January 2018

Elena Poddubskaya

17

1 reference

8 January 2018

Scott N Gettinger

19

1 reference

8 January 2018

Cécile Dorange

25

1 reference

8 January 2018

Christopher T Harbison

26

1 reference

8 January 2018

Friedrich Graf Finckenstein

27

1 reference

8 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26412456

language of work or name

1 reference

30 April 2017

publication date

27 September 2015

1 reference

8 January 2018

The New England Journal of Medicine

published in

1 reference

8 January 2018

volume

373

1 reference

8 January 2018

page(s)

1627-1639

1 reference

8 January 2018

issue

17

1 reference

8 January 2018

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Pembrolizumab for the treatment of non-small-cell lung cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

The blockade of immune checkpoints in cancer immunotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Erlotinib in previously treated non-small-cell lung cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705936

26 November 2018

Identifiers

DOI

10.1056/NEJMOA1507643

1 reference

8 January 2018

OpenCitations bibliographic resource ID

8443

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

8 January 2018

PubMed ID

26412456

1 reference

8 January 2018